Advertisement

Topics

Search Results for "Immune Sera Are Used For All Of The Following EXCEPT"

19:26 EDT 28th March 2017 | BioPortfolio

Matching Channels

Matching News

Labcorp buys into Sera, to distribute preterm birth test

Sera Prognostics Inc. (Salt Lake City, Utah) raised $40 million in a series C round led by Laboratory Corp. of America Holdings (NYSE:LH). Also participating were existing investors Domain Associates,...

Sera Prognostics raises $40mm in Series C round led by LabCorp

Proteomics test developer Sera Prognostics Inc. (diagnostics to predict potential preterm birth and other pregnancy-related complications) raised $40mm in a Series C round from existing backers led by...

60 years ago, first landing at the South Pole paved the way for world-class Antarctic science

On October 31, 1956, seven U.S. naval aviators did what many thought was impossible…they landed a plane for the first time at the bottom of the world. The pilot, Lt. Cmdr. Conrad C. “...

Néovacs sera présente à deux conférences investisseurs

NEOVACS — Friday, January 6th 2017 at 7:00am UTC COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE Néovacs sera présente à deux conférences investisseurs:  LifeSci Adviso...

LabCorp licenses exclusive US distribution rights to Sera's PreTRM premature birth risk diagnostic

Concurrent with its lead investment in Sera Prognostics Inc.'s $40mm Series C round, Laboratory Corp. of America Holdings licensed exclusive US distribution rights to the company's PreTRM premature bi...

GENFIT annonce l’admission de deux nouveaux abstracts dont l’un sera présenté en session orale lors du congrès de l’AASLD 2016

GENFIT — Thursday, October 20th 2016 at 3:45pm UTC GENFIT annonce l’admission de deux nouveaux abstracts dont l’un sera présenté en session orale lors du congrès de l’AASLD ...

Global Bioenergies proche de l’effet de booster

ÉDITION ABONNÉS –  « Le véritable déploiement de notre procédé ne sera effectif qu’avec une usine commerciale de pleine taille. L’un des enjeux de 2017 sera de fédérer ass...

BRIEF-Sera Prognostics files to say it raised about $23 million in equity financing from total offering of $45 million

* Sera Prognostics Inc files to say it raised about $23 million in equity financing from total offering of $45 million - SEC filing Source text: (http://bit.ly/2jUygig)

Matching PubMed Articles

Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. To improve its outcome, the reliable biomarkers are urgently needed. In this study, we aimed to elucidate the key molecu...

Characterization of Autoantigens Targeted by Anti-Citrullinated Protein Antibodies In Vivo: Prominent Role for Epitopes Derived from Histone 4 Proteins.

Anti-citrullinated protein antibodies (ACPA) have become an integral part of the clinical definition of rheumatoid arthritis, and are hypothesized to be important in the immunopathogenesis of this aut...

The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.

A gold standard of antiviral vaccination has been the safe and effective live-attenuated 17D-based yellow fever virus (YFV) vaccines. Among more than 500 million vaccinees, only a handful of cases hav...

B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.

Identifying antigenic proteins and mapping their epitopes is important for the development of diagnostic reagents and recombinant vaccines. B-cell epitopes of African horse sickness virus (AHSV) have ...

Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus.

In a pilot ProtoArray analysis, we identified 6 proteins out of 9483 recognized by autoantibodies (AAb) from patients with systemic sclerosis (SSc). We further investigated the 6 candidates by ELISA o...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement